No Data
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Rec
NYSE American New 52-Week Highs And Lows
New Highs 5 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Actinium Pharmaceuticals ATNM 9.99 307,312 Am
Express News | Actinium Pharmaceuticals Inc : Stephens Initiates Coverage With Overweight Rating; Price Target $25
Actinium Pharmaceuticals Initiated at Overweight by Stephens & Co.
Actinium Pharmaceuticals Initiated at Overweight by Stephens & Co.
Express News | Stephens & Co. Initiates Coverage On Actinium Pharma With Overweight Rating, Announces Price Target of $25
Actinium Announces Announced Five Abstracts Accepted For Presentation At 2024 SNMMI Annual Meeting
- Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey- Improved survival demonstrated with both Iomab